Health and Wellness Survey (NWHS) in Brazil. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of work/productivity was measured by the validated Work Productivity and Activity Impairment instrument. Medical resource utilization was measured by health care provider, emergency room visits and hospitalization in the past 6 months. RESULTS: Of the 12,000 respondents, 215 (1.6%) were identified as AD patients. Age 62.1% were white and the highest proportion of caregivers was 45-54yrs old (36.2%), and they are significantly older than non-caregivers (44.7 vs. 40.8; p = 0.05). AD caregivers group reported more specific co-morbidities (insomnia 33.8%, cardiac arrhythmia 20.7%), similar mean scores of PCS (49.8 vs 49.7) and MCS (47/3 vs 46.9), similar percentage of emergency room visits (21.5% vs. 21.8%), and similar percentage of hospitalization visits (9.9 vs. 9.8) over the past 6 months compared to the group of non-caregivers of AD patients. Furthermore, caregivers of AD patients group reported 22.3% impairment in daily activities compared to 17.1% in the group of non-caregivers of AD patients. CONCLUSIONS: From the Brazilian NHWS results, AD caregivers suffer from impairment in QOL, work/productivity loss and more specific co-morbidities. Findings indicate there is still an unmet medical need in AD caregivers in Brazil.

PND43
DEVELOPMENT OF THE SATISFACTION WITH INJECTION EXPERIENCE QUESTIONNAIRE FOR PATIENTS WITH MULTIPLE SCLEROSIS
Buq PQ1, Conner BR2, Mathena J1, Castelli-Haley P1, Denney DR3
1Teva Pharmaceuticals Horsham, PA, USA, 2Teva Pharmaceuticals, Kansas City, MO, USA, 3University of Kansas, Lawrence, KS, USA
OBJECTIVES: The purpose of this study was to develop a questionnaire to evaluate satisfaction with injection experience for patients with Multiple Sclerosis (MS). SIE was developed using the Delphi method to determine the domains that were relevant to MS injection satisfaction. The development of the questionnaire was based on patient input, and input from clinicians and investigators. RESULTS: A total of 244 patients participated in the SIE development process. The SIE questionnaire was developed and consists of 5 items. The SIE questionnaire was found to be reliable (Cronbach’s alpha = 0.77) and valid (item-total Spearman correlations > 0.4 for all items, test-retest reliability, y = 0.8; range 1.0 to 5.0). All item-total Spearman correlations were greater than 0.30 (range 0.34 to 0.79) and the SIE questionnaire demonstrated excellent internal reliability (Cronbach’s alpha = 0.82). Based on the eigenvalues and score plot of the principal components analysis, a single component was extracted, with 58.6% of total variation explained. CONCLUSIONS: From the extensive pilot testing of this SIE questionnaire, it appears to be reliable, valid, and sensitive to change in MS patients. The SIE questionnaire is an acceptable tool to evaluate and improve patient satisfaction with injection experience.

PND44
ASSESSING VARIATIONS IN TRANSITIONS IN EMPLOYMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS TREATED WITH EITHER LAQUINIMOD, INTERFERON BETAL-1A OR PLACEBO: EXPLORATORY EVIDENCE FROM THE UNITED STATES SUBSTUDY OF BRAVO
Carroll CA1, Glenn-Burkey MA2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics LLC, Leawood, KS, USA
OBJECTIVES: To assess in short-term changes in employment status in relapsing-remitting multiple sclerosis (RRMS) patients are treated with either oral, once daily, placebo, once daily or Interferon beta-1a 0.4mg once daily, oral, placebo once daily or Interferon beta-1a 0.4mg intramuscular injection weekly in the randomized, placebo-controlled BRAVO trial. U.S. patients completed the validated Work Productivity and Activity Impairment Scale-General Health (WPAI-GH) at baseline and every three months thereafter. At study completion, patient’s transitions from 1) unemployment to employment, 2) no transition in employment, and 3) transitions from employment to unemployment were assessed using univariate statistics. RESULTS: Sixty-two patients residing in the United States completed the WPAI-GH with comparable study populations assigned to each of the three study arms. Statistically significant differences were observed in the three transitions when consideration was given to changes in employment status (p < 0.001). Seventy-seven percent of patients treated with Avonex reported no change in employment status during the course of the study while 81% of patients in each of the Laquinimod and placebo groups reported a change in employment status. A greater proportion of patients treated with Avonex reported the greatest transition from employment to unemployment (18%) compared to Laquinimod (9%) and placebo (6%). CONCLUSIONS: Managed care pharmacists consider multiple factors when making formulary decisions. While safety and efficacy are the primary considerations, other factors that influence patients and employers are frequently evaluated. While exploratory in nature, variations in changes in employment status may occur in RRMS patients treated with alternative disease modifying therapies. These findings, however, are preliminary in nature and warrant future consideration through additional research.

PND45
MOBILITY IMPAIRMENT AND HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS
Coleman C1, Sidover M2, Roberts MS3, Baker WL4
1University of Connecticut School of Pharmacy, Hartford, CT, USA, 2Acorda Therapeutics, Inc., Waltham, MA, USA, 3University of Connecticut/Harford Hospital Evidence Based Practice Center, Hartford, CT, USA, 4University of Connecticut School of Pharmacy & Medicine, Farmington, CT, USA
OBJECTIVES: Emerging data suggest that even mild or subclinical mobility loss associated with multiple sclerosis (MS) may adversely affect health-related quality of life (HRQoL). We evaluated the impact and timing of mobility impairment on HRQoL. METHODS: The North American Committee on Multiple Sclerosis (NARCOMS) registry was used to conduct a cross-sectional study of participants who completed the biannual update and supplemental Spring 2010 surveys. The NARCOMS Performance Scale for mobility was used to grade severity of mobility impairment. HRQoL assessments included the Short Form(SF)-12, physical and mental subscales (PCS and MCS), the EuroQol (EQ) SD, EQ-Visual Analog Scale (VAS), and SF-6D. RESULTS: A total of 3483 registrants completed both surveys. Compared with those rating themselves as “normal” (n = 628) on the mobility performance scale, participants describing their disability as “minimal” (n = 560), “mild” (n = 535), “moderate” (n = 535), “severe” (n = 543), and “total” (n = 105) each reported poorer HRQoL scores on the PCS and MCS (PCS range: 53.6-30.5, MCS range: 46.3-40.3; p < 0.001 for all). The largest relative decrement in PCS and MCS came at the transition from “normal” to “minimal” (PCS: 15.1%, MCS: 6.2%) and “minimal” to “mild” mobility impairment (PCS: 15.4%, MCS: 9.8%) with the detrimental effect on HRQoL being most profound on the PCS, and little effect on the MCS after the earlier stages of mobility impairment. Poorer health utility was also reported in participants in impaired mobility categories compared to “normal” when examined using each of the utility measures EQ-5D (0.89-0.53), EQ-VAS (64.2-26.1), and SF-6D (0.88-0.001 for all). The largest decrements in utility came at the transition from “normal” to “minimal” (9.6%-10.3%) and “minimal” to “mild” mobility impairment (an additional 8.6%-10.7%). CONCLUSIONS: These data suggest that mobility impairment may negatively affect HRQoL, with the most profound decrements occurring at earlier stages of mobility loss.

PND46
LONGITUDINAL ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN AN OBSERVATIONAL COHORT OF PATIENTS WITH CYSTIC FIBROSIS
Sawicki GS1, Ransohoff S2, Mccrumlin AH3, Wagnier JS4, Mccolley SA5, Pasta DJ6, Quittner AL7
1Children’s Hospital Boston, Boston, MA, USA, 2ICON Late Phase & Outcomes Research, Barcelona, Catalonia, Spain, 3University of Rochester, Rochester, NY, USA, 4University of Colorado School of Medicine, Denver, CO, USA, 5Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 6ICON Late Phase & Outcomes Research, San Francisco, CA, USA, 7University of Miami, Miami, FL, USA
OBJECTIVES: To evaluate associations between changes in health status over time and health-related quality of life (HRQL) using the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a disease-specific patient-reported outcome (PRO) measure of HRQL. METHODS: Using the Epidemiologic Study of Cystic Fibrosis (ESCF) data, we evaluated participants who completed age-appropriate CFQ-R assessments 2 on 2 occasions separated by 9 to 15 months. We developed multivariable regression models to test whether associations existed between 1) changes in respiratory symptoms/changes and symptoms in the respiratory health domains of the CFQ-R; 2) changes in nutritional health status and changes in the nutritional health domains of the CFQ-R; and 3) changes in treatment complexity and changes in the Treatment Burden scale of the CFQ-R. RESULTS: We analyzed 1947 pairs of assessments: 337 child (8.9, range 6-13 years), 581 parent (mean age of child 8.8, range 6-13 years), 398 adolescent (mean age 15.3, range 14-17 years), and 631 adult (mean age 26.9, range 18-73 years). On average, we found little change in both health status indicators and CFQ-R domain scores over 1 year. Significant associations over time, however, were found with declining weight and worsening scores on the CFQ-R nutritional health domains, and increasing treatment complexity and worsening CFQ-R Treatment Burden scores for parent respondents. CONCLUSIONS: Health status and HRQL changes were small over a 1-year period in this CF population. Changes in respiratory symptoms and weight, however, were associated with significant changes on relevant CFQ-R scales, indicating that this PRO is sensitive to changes in health status over time.

MOBILIZATION DISORDERS – Health Care Use & Policy Studies
PND47
RESCUE MEDICATION USE IN THE ACUTE TREATMENT OF MIGRAINE DURING A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Kori S, Kellerman D, Chen S, Lu B
1MOP Pharmaceuticals, Inc., Mountain View, CA, USA
OBJECTIVE: This post hoc analysis evaluated the use of rescue medication in the acute treatment of migraine episodes reported during a randomized, placebo-controlled, double-blind trial of MAP0004, an investigational, orally inhaled dihydroergotamine. METHODS: Rescue medication use (RMU) was permitted in this study if migraine symptoms were not relieved 2 hours after study drug administration. RMU in the MAP0004 and placebo treatment groups were adjusted for baseline pain scores and compared according to demographic and baseline disease characteristics (eg, age, gender, race, migraine history, baseline pain severity). The